The present disclosure provides biochemically responsive Fe(II) and Fe(III) complexes useful as magnetic resonance imaging probes for diagnosis and monitoring acute and chronic inflammatory diseases affecting various organs and tissues.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
Formulations of HDAC6 inhibitors passing through the blood brain barrier in hypothalamus and inhibiting HDAC6 in the arctuate AgRP neurons in the hypothalamus, are effective to cause weight loss in obese individuals. These inhibitors also restore leptin sensitivity in leptin-resistant individuals.
A61K 31/166 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p.ex. procaïnamide, procarbazine, métoclopramide, labétalol
Magnetic resonance imaging (MRI) is used to image the slow flow of cerebrospinal fluid (CSF) in subarachnoid and perivascular spaces, amongst other regions of the brain and central nervous system. The slow CSF flow imaging can be provided by using low velocity' encoding (VENC) and an efficient data acquisition. Tailored image processing can be used to further improve the accuracy, specificity, and visualization of CSF flow dynamics.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
G16H 30/00 - TIC spécialement adaptées au maniement ou au traitement d’images médicales
6.
SYSTEM AND METHOD FOR CONTROL OF IONIZING RADIATION DOSE IN MEDICAL APPLICATIONS USING SYNTHETIC LOCALIZERS
Methods, system, and non-transitory media are provided for tube-current-modulation (TCM) calculation in computed tomography (CT) imaging. The radiation dose exposure is adjusted by identifying dose varying anatomical markers such as arms or removable objects that are not consistently positioned between localizer and actual scanning. Provided herein are means of reducing the effect of those anatomical markers on the TCM calculation by generating a synthetic localizer from an acquired localizer of a patient wherein the anatomical marker has been modified to match the actual scanning status. Modification of the dose-varying anatomical marker may include changing the position from an arms-down to arms up position or complete image signal removal of the arms or other markers from the localizer.
Described herein are methods and compositions for treating Alzheimer's Disease (AD), as well as compositions comprising a reelin-derived peptide and methods of use thereof.
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
One or more devices, systems, methods, and storage mediums for performing robotic control and/or for performing localization and lesion targeting are provided herein. Examples of such control, localization and lesion targeting include, but are not limited to, correction of one or more sections or portions of a continuum robot as the continuum robot is moved and performing localization and lesion targeting in a bronchial pathway using a continuum robot. Examples of applications include imaging, evaluating, and diagnosing biological objects, such as, but not limited to, for bronchial applications, and being obtained via one or more optical instruments, such as, but not limited to, optical probes, catheters, endoscopes, and bronchoscopes. Techniques provided herein also improve processing, imaging, and lesion targeting efficiency while achieving images that are more precise, and also achieve devices, systems, methods, and storage mediums that reduce mental and physical burden and improve ease of use.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments
A61B 34/00 - Chirurgie assistée par ordinateur; Manipulateurs ou robots spécialement adaptés à l’utilisation en chirurgie
9.
ENGINEERED BIFUNCTIONAL RECEPTORS AND USES THEREOF
Described in several example embodiments herein are engineered bifunctional receptors that can include an E3 ligase binding domain and a target binding domain operatively coupled to the E3 ligase binding domain. In some embodiments, the engineered bifunctional receptors are capable of targeted degradation of a target protein. Also described in several example embodiments herein are compositions, formulations, and cells that can include or generate the engineered bifunctional receptors and uses thereof.
The present document relates to covalent compounds and uses thereof, including methods of targeting or engaging one or more targets with a covalent compound. Also provided herein are methods of treating a disease using such a compound and methods of identifying one or more targets using such a compound.
C07C 233/11 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone de radicaux hydrocarbonés non substitués avec des atomes de carbone de groupes carboxamide liés à des atomes de carbone d'un squelette carboné non saturé contenant des cycles aromatiques à six chaînons
A61K 31/165 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide
11.
METHOD AND SYSTEM FOR MOTION-ROBUST SUPER-RESOLUTION MAGNETIC RESONANCE IMAGING
The present disclosure provides a method for generating MRI images of a subject. The method includes accessing MRI images of the subject that have a first resolution, where each of the MRI images was acquired with a selected sampling pattern. The method further includes estimating motion between the MRI images to determine a motion transformation that corresponds to motion of the subject between the MRI images. The method further includes applying a model-based super-resolution reconstruction to the MRI images. The reconstruction accounts for the motion transformation and generates an image of the subject within the image volume that has a second resolution greater than the first resolution.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
G16H 30/00 - TIC spécialement adaptées au maniement ou au traitement d’images médicales
12.
METHODS FOR ACCELERATED TIME-RESOLVED MULTI-ECHO MAGNETIC RESONANCE IMAGING BY AUGMENTING TEMPORAL CORRELATION
Accelerated time-resolved multi-echo magnetic resonance imaging (MRI) uses augmenting of the temporal correlation across echoes, for example, by applying gradient blips that sample the spatiotemporal space in a new trajectory to reduce dead time and echo spacing. Additionally or alternatively, acceleration may be achieved by optimization of the encoding pattern to reduce temporal distance and/or using a spatiotemporal partial Fourier acquisition.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
G16H 30/00 - TIC spécialement adaptées au maniement ou au traitement d’images médicales
13.
SYSTEM AND METHOD FOR MULTIPHOTON PARALLEL TRANSMIT EXCITATION FOR MRI
A method for generating a magnetic resonance image of a subject using a magnetic resonance imaging (MRI) system includes receiving, using the MRI system, at least one parameter for a multiphoton parallel transmit excitation comprising a multiphoton excitation pulse configured to correct spatial inhomogeneities and performing, using the MRI system, a pulse sequence comprising the multiphoton parallel transmit excitation to acquire data from the subject. The multi photon excitation pulse of the multi photon parallel transmit excitation is performed using a radio frequency (RF) coil and a set of one or more shim coils of the MRI system. The method further includes generating, using a processor, an image of the subject using the acquired MR data. In some embodiments, the multiphoton excitation pulse includes an off-resonance RF excitation pulse performed using the RF coil and a plurality of low-frequency excitation pulses performed using the set of one or more shim coils. The plurality of low-frequency excitation pulses are performed simultaneously with the off-resonance RF excitation pulse.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
G16H 30/00 - TIC spécialement adaptées au maniement ou au traitement d’images médicales
14.
LIBRARY-SCALE METHODS FOR POLYPEPTIDE FUNCTIONAL ANALYSIS
Disclosed herein are methods, compositions, systems, and kits related to functional testing of polypeptide-target interactions, such as antigen/immune receptor interactions, in a single-cell format.
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
15.
IMMUNOCAPTURE METHODS TO ENRICH FOR ENGINEERED EXTRACELLULAR VESICLES
Extracellular vesicles (EVs) are natural liposome-like vesicles secreted by cells into the extracellular space. Provided herein are techniques to enrich cargo-loaded EVs over non-loaded EVs and contaminants. To achieve EVs were engineered to display their surface an antigenic tag for fast and efficient EV isolation by immunocapture and a fluorescent protein in the internal space of the EV. Cargo was loaded into the lumen of the EVs by fusing the cargo with an antibody or nanobody that has an affinity for the fluorescent protein of the internal space. To prevent potential antigenicity of the EVs, a TEV cleavage site was included allowing the removal of exposed antigenic tag from immunocaptured EVs, while preserving their luminal cargo.
B01D 15/38 - Adsorption sélective, p.ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p.ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
16.
MINIMALLY INVASIVE DEVICE FOR NERVE IDENTIFICATION, STIMULATION, AND MANIPULATION
Systems and methods for an insertable medical device are described. The device comprises a device body configured to be insertable into a subject; proximal and distal openings; a cavity extending through the device body and in communication with the proximal opening and the distal opening, the cavity and the proximal opening being dimensioned to receive an instrument therein; a plurality of electrically conductive pads configured to be positioned a predetermined location relative to the proximal and distal openings, and configured to sense an electrical characteristic of the subject; an I/O device configured to: output signal data from the electrically conductive pads to a processing device operating a ML algorithm, the signal data including data corresponding to the electrical characteristic of the subject, and receive response data generated by the ML algorithm indicating a tissue type proximate respective electrically conductive pads based on an analysis of the signal data.
A radiation oncology workflow management system is provided. The system may include interactive graphical interface and a particularly programmed processor, thereby to perform operations including displaying a window containing a user interface (UI) environment on a computer screen, parsing an input received from a user via the UI environment, thereby to determine which of a plurality of atomic application functions is indicated by the input, automatically interacting with an atomic application associated with the atomic application function determined to be indicated by the input, and automatically displaying information received from the atomic application via the UI environment.
G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p.ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients
G16H 80/00 - TIC spécialement adaptées pour faciliter la communication entre les professionnels de la santé ou les patients, p.ex. pour le diagnostic collaboratif, la thérapie collaborative ou la surveillance collaborative de l’état de santé
18.
METHODS AND COMPOSITIONS FOR HIGH-THROUGHPUT DISCOVERY OFPEPTIDE-MHC TARGETING BINDING PROTEINS
The present invention discloses methods and platforms for generating protein binding proteins with specificity for native peptide-MHC (pMHC) complexes. The pMHC binding proteins can be used in bi-specific antibodies or for generating CAR T cells capable of binding to peptides bound to specific MHC alleles.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
19.
ARTIFICIAL INTELLIGENCE ENABLED DISCRIMINATION OF DISEASE AND DISEASE ETIOLOGY
The subject matter disclosed herein relates using waveform data of a subject to detect one or more diseases or disease etiologies. Particular examples relate to providing a system, a computer-implemented method, and a computer program product to waveform data to detect and differentiate particular diseases and disease etiologies with machine learning models.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p.ex. pour analyser les cas antérieurs d’autres patients
20.
MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS (OHSV) AND METHODS OF USE THEREOF
Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer/promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).
21.
ADMINISTRATION OF GLUTATHIONE TRISULFIDE TO AMELIORATE PERIPHERAL NEUROPATHY
Methods and devices for the administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) to treat peripheral neuropathy, e.g., chemotherapy-induced peripheral neuropathy (CIPN), e.g., by oral or nasal administration. The methods can be used, e.g., to reduce pain associated with CIPN, or reduce the risk of development of CIPN.
22.
4-1BBL AND IL-12 THERAPY FOR TREATMENT OF GLIOBLASTOMA
Provided herein are methods of treating glioblastoma including administering to a subject having glioblastoma a therapeutically effective amount of a pharmaceutical composition comprising 4-1BBL, optionally in combination with recombinant IL-12. The 4-1BBL can be provided to the subject via an adeno-associated virus, for example AAV-F, and the IL-12 can be provided by intratumoral injection.
23.
PROBES AND METHODS TO IDENTIFY LIGANDABLE FATTY ACYLATION SITES FOR THERAPEUTIC TARGET IDENTIFICATION
The present disclosure relates to compounds of Formula I and methods comprising the use of these compounds to identify ligandable fatty acylation sites.
24.
SYSTEM AND METHOD FOR DETERMINING PERFUSED TISSUE VIABILITY
The disclosure provides perfusion systems and methods for continuous or intermittent perfusion to monitor and extend the viability of tissue for transplants. Intermittent perfusion involves generating perfusion cycles which alternate between baseline and high oxygen gas partial pressure in the circulating perfusate. The system comprises a perfusion fluid source and an inflow conduit in fluid communication with the perfusion fluid source and a tissue sample, wherein the inflow conduit is configured to deliver perfusion fluid to the tissue sample. The system further comprises an outflow conduit in fluid communication with the tissue sample, wherein the outflow conduit is configured to carry perfusion fluid away from the tissue sample. A first gas sensor is in fluid communication with the inflow-conduit and measures a. concentration of a gas in perfusion fluid, in the inflow conduit, and a second gas sensor is in contact with the tissue sample and measures a concentration of a gas in the sample.
25.
GENE THERAPY FOR GENETIC AND ACQUIRED VASCULOPATHIES
Described herein are gene-targeted therapies and compositions that can include a vessel-specific viral vector, preferably in combination with a HDAC9-derived promoter to transduce SMC and deliver a base editor that corrects mutant alleles or a Cas nuclease that knocks out the mutant allele.
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
26.
METHODS FOR TREATMENT SELECTION FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and/or for inclusion in a clinical trial using the agent to treat CLL.
C12Q 1/527 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une lyase
28.
MICROMOTOR AND OPTICAL ARRANGEMENT FOR FAST CIRCULAR SCANNING OF LIGHT BEAMS IN SMALL DIAMETER FLEXIBLE CATHETERS
The disclosure presents a shaftless, brushless motor for rotating any optical or sensing element (e.g., a lens or mirror) at a distal end of a waveguide that also delivers electromagnetic radiation (e.g., light). Herein, the waveguide itself functions as the axle on which rotating components rotate, thereby avoiding blind spots and overcoming limitations in existing "micromotors". The shaftless, distally driven motor significantly reduces motor size, while extremely small inertial loads and bearing sizes allow for high pitch cylindrical scanning with longitudinal velocity uniformity.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments
G02B 6/00 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES - Détails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p.ex. des moyens de couplage
29.
METHOD AND APPARATUS FOR MODULATING SIGNALS OF LUMINESCENT POLYMER/DYE FORMULATIONS USING LIGHT SCATTERING PARTICLES
A sensing system and method for sensing an analyte. The sensing system includes; a sensing material having one or more layers, the sensing material including; a light emitting material and a plurality of signal enhancing particles disposed within a polymer matrix. The sensing method includes: providing a sensing material including one or more layers, the sensing material including a light emitting material and a plurality of signal enhancing particles disposed within a polymer matrix, the light emitting material being sensitive to an analyte; exposing the sensing system to the analyte; and measuring a change in a light emission from the light emitting material based on exposing the sensing system to the analyte.
G01N 21/27 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection photo-électrique
30.
SUPRAMOLECULAR HYBRID HYDROGELS FOR BURN AND WOUND DRESSINGS
Disclosed are supramolecular hybrid hydrogels (SHH), wound dressings, comprising supramolecular hybrid hydrogels; and methods of treating wounds, including burns.
A61F 13/00 - Bandages ou pansements; Garnitures absorbantes
A61L 15/22 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p.ex. serviettes hygiéniques, tampons contenant des matériaux macromoléculaires
A61L 26/00 - Aspects chimiques des bandages liquides ou utilisation de matériaux pour les bandages liquides
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
THE GENERAL HOSPITAL CORPORATION (USA)
Inventeur(s)
Kleinstiver, Benjamin
Guy, Jacqueline
Bird, Adrian
Abrégé
The present disclosure relates to compositions for use in the treatment of a class of Rett syndrome mutations, namely C-terminal deletions, comprising a base editor to alter a stop codon in a mutant MECP2 gene. This alteration does not return the gene to its wild-type (WT) form, but re-establishes normal levels of a version which is functionally equivalent to a wild¬ type version of the MeCP2 protein.
An acoustic filter can include a first substrate including a first plurality of holes directed, therethrough, a second substrate including a second plurality of holes directed therethrough, a chamber defined between the first substrate and the second substrate, and a membrane positioned within the chamber. The membrane can have a dimension other than the thickness of the membrane that can be less than a corresponding dimension of the chamber. The acoustic filter can be configured to attenuate a first acoustic wave that passes through the acoustic filter, the first acoustic wave can have a first amplitude above an amplitude threshold. The acoustic filter can be configured to passthrough a second acoustic wave without substantially attenuating the second acoustic wave, the second acoustic wave can have a second amplitude below' the amplitude threshold.
Described herein are perfusable 3D tubule-on-chip models comprising at least one tubule consisting of one patent lumen circumscribed by organoid- derived cells, and a multifluidic platform comprising at least one individually addressable chip. The models may further include an unseeded tubule, where the seeded tubule and the unseeded tubule are co-localized on the chip, and wherein the tubule and the unseeded tubule are embedded within a gelatin-fibrin extracellular matrix (ECM). Also, described here are methods of producing the described perfusable 3D tubule-on-chip models, and uses of the same.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
Provided herein are computer-implemented methods for assigning maternal or fetal origin to one or more genetic variants in cell free DNA (cfDNA) from a sample from a pregnant mammal, preferably a pregnant human, using a probabilistic model for assigning maternal or fetal origin to genetic variants in DNA from a sample obtained from a pregnant mammal, wherein the model assigns maternal or fetal origin based on a combination of fetal fraction and DNA fragment size.
G16B 20/10 - Ploïdie ou détection du nombre de copies
G16B 30/10 - Alignement de séquence; Recherche d’homologie
C12Q 1/6804 - Analyse d’acides nucléiques utilisant des immunogènes
G16B 40/00 - TIC spécialement adaptées aux biostatistiques; TIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p.ex. extraction de connaissances ou détection de motifs
G16B 5/00 - TIC spécialement adaptées à la modélisation ou aux simulations dans la biologie des systèmes, p. ex. réseaux de régulation génétique, réseaux d’interaction entre protéines ou réseaux métaboliques
35.
COMPOSITIONS AND METHODS FOR TREATING TRINUCLEOTIDE REPEAT DISORDERS
Methods and compositions for reducing expansion of nucleotide repeats in a cell, comprising base editors and a guide RNA (gRNA) that directs the Cas-based enzyme to the splice acceptor site for mutL homolog 3 (MLH3) exon 7 or to the MLH3 endonuclease domain.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
37.
INJECTABLE THERMOSENSITIVE HYDROGELS FOR A SUSTAINED RELEASE OF IRON NANOCHELATORS
Disclosed herein are injectable hydrogel formulations prepared by integrating crosslinked hyaluronic acid into Pluronic F127 for an extended release of DFO nanochelators. Methods of manufacture and of use are also provided.
Disclosed herein are implantable vascular devices and methods of use thereof. Exemplary embodiments of the implantable vascular device comprise a tubular stent component, and one or more of a cell compartment, a graft component, or a bioscaffold, along with one or more support members providing a fixed position between the tubular stent component and the cell compartment, graft component, or bioscaffold. Preferably, the one or more support members provide a collapsible fixed position. Methods of use include methods of implanting and methods of removing, the device, as well as methods of reseeding the device, in some embodiments.
A device for carbon dioxide monitoring is disclosed. The device comprises: a photoluminescent carbon dioxide-sensitive probe comprising a polymer matrix and a sensing dye; a photon source configured to direct photons at the probe; a photodetector configured to detect light emitted from the probe when the photon source directs photons at the probe; a carbon dioxide permeable light redirection layer, wherein the carbon dioxide-sensitive probe is positioned between the light redirection layer and the photodetector; and a controller in electrical communication with the photon source and the photodetector, the controller being configured to execute a program stored in the controller to calculate a level of carbon dioxide adjacent the probe from an electrical signal received from the photodetector. In one form, the polymer matrix comprises a polymer selected from the group consisting of acrylate polymers, methacrylate polymers, polyurethane polymers, and blends and copolymers thereof.
A61B 5/1459 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang en utilisant des capteurs optiques, p.ex. des oxymètres à photométrie spectrale invasifs, p.ex. introduits dans le corps par un cathéter
G01J 1/58 - Photométrie, p.ex. posemètres photographiques en utilisant une luminescence produite par la lumière
C08F 20/18 - Esters des alcools ou des phénols monohydriques des phénols ou des alcools contenant plusieurs atomes de carbone avec l'acide acrylique ou l'acide méthacrylique
A61B 5/1495 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang Étalonnage ou test des sondes in vivo
40.
RETROGRADE TETHERED CAPSULE ENDOMICROSCOPY SYSTEMS AND METHODS
A system for performing retrograde tethered capsule endomicroscopy, including: a capsule including at least one outwardly-facing helical thread; a drive shaft coupled to the capsule and configured to rotate the capsule; and an optical system disposed within the capsule and configured to obtain circumferential imaging information. A method for performing retrograde tethered capsule endomicroscopy, comprising: providing a capsule comprising at least one outwardly-facing helical thread and an optical system disposed within the capsule; rotating the capsule using a drive shaft coupled to the capsule; and obtaining circumferential imaging information using the optical system disposed within the capsule.
A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments
A61B 1/07 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement utilisant des moyens conduisant la lumière, p.ex. des fibres optiques
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
Methods, systems, and apparatus, including computer programs encoded on computer storage media, for proteome mapping. One of the methods includes: identifying one or more target peptide sequences for a sample; estimating an elution order of one or more expected peptides from a chromatography column; and initiating generation of a first set of mass spectrometry spectra for the sample. The method also includes detecting peaks within the first set of mass spectrometry spectra to determine a real-time status with respect to the estimated elution order; selecting one or more peptide ions that are (i) observed in the first set of mass spectrometry spectra and (ii) included among the one or more peptides expected to be present in the sample; and initiating generation of a second set of mass spectrometry spectra for the one or more selected peptide ions.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 27/623 - Spectrométrie de mobilité ionique combinée à la spectrométrie de masse
G01N 33/72 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir les pigments du sang, p.ex. l'hémoglobine, la bilirubine
G16B 40/10 - Traitement du signal, p.ex. de spectrométrie de masse ou de réaction en chaîne par polymérase
G01N 30/88 - Systèmes intégrés d'analyse, spécialement adaptés à cet effet, non couverts par un seul des groupes
42.
BIOSENSOR CARTRIDGE AND BIOSENSOR DEVICE COMPRISING SAME
A biosensor cartridge is disclosed. The biosensor cartridge, which detects biological material so as to generate an electrochemiluminescence signal, according to one aspect of the present invention, comprises: an electrode unit including a plurality of electrodes; and a dividing unit disposed on the electrode unit so as to divide the entire space provided on the electrode unit into a signal chamber and N-number of reaction chambers, which encompass the signal chamber, wherein the electrode unit includes a first electrode of which at least a portion is disposed in the reaction chambers, a second electrode disposed in the signal chamber, and N-number of connection electrodes disposed to electrically link the chemical reaction in the reaction chambers and the electrochemiluminescence signal generated in the signal chamber.
G01N 21/66 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente excité électriquement, p.ex. par électroluminescence
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
Methods for increasing expression of a target gene, the method comprising introducing a CCCTC-binding factor (CTCF) binding site (CTCF-BS) into a promoter region of the target gene, e.g., within 500, 250, 200, 150, 100, 50, or 25 nucleotides of the transcription start site (TSS) for the target gene, and optionally expressing in or introducing into the cell a CTCF protein or variant thereof.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
C07K 14/46 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés
C12N 15/12 - Gènes codant pour des protéines animales
44.
METHODS AND SYSTEMS OF ENHANCING ELECTROMAGNETIC RADIATION SIGNALS FROM EXTRACELLULAR VESICLES
Systems, methods, and devices are described herein for use in detecting and/or monitoring target extracellular vesicles ("EVs"), e.g., to detect and/or monitor treatment for a disease, e.g., for cancer, in a subject. The systems can include nano-plasmonic arrays of nanostructures arranged to form a periodic array on a substrate, and each nanostructure can include a nanopillar, a spacer layer, e.g., coated onto a metallic layer, and a plurality of metal nanoparticles bound to each of the nanopillars. The nano-plasmonic arrays amplify specific wavelengths of electromagnetic radiation and can be used to capture and image target EVs.
G01N 21/63 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente excité optiquement
G01N 15/02 - Recherche de la dimension ou de la distribution des dimensions des particules
G01N 15/14 - Recherche par des moyens électro-optiques
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
Provided herein are compositions and methods of use thereof for treating Autosomal recessive polycystic kidney disease (ARPKD) by targeting Rac family small GTPase 1 (RAC1 ) and/or Fos proto-oncogene, AP-1 transcription factor subunit (FOS) by administering a therapeutically effective amount of an inhibitor of RAC1 and/or FOS to a subject in need thereof.
T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with diverse immunopathologies across the spectrum of infectious disease and autoimmunity. Here, Applicants employ monoallelic immunopeptidomics to retrieve over 200,000 unique peptides presented by 41 HLA-II heterodimers covering major alleles across diverse ancestries. Applicants leveraged this expansive dataset to develop computational models that predict peptide antigens based on HLA-II binding properties and infer informative features of the protein antigens from which these peptides derive. Combining both peptide and (contextual) protein features, Applicants develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen SARS-CoV-2.
C07K 16/26 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des hormones
G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
48.
SYSTEMS FOR ELECTROENCEPHALOGRAPHY AND METHODS FOR USE AND MANUFACTURE OF THE SAME
Systems and methods are provided for forming a system for transmitting electrical signals to or from the head of a subject. The system includes a base layer. A layer of conductive, non-ferrous material may be deposited along an upper surface of the base layer using a thin-film deposition technique, which is patterned into a conductive trace that extends between a proximal end and a distal end of the base layer. A thick film forming an electrode is positioned relative to a distal end of the conductive trace.
An apparatus and method for removing dermal tissue from a dermis layer. The apparatus can include a hollow needle with a proximal end, a distal end, and a central lumen extending from the proximal end through the distal end. Properties of the hollow needle can be selected such that the hollow needle can be inserted into dermal tissue to remove a portion of tissue from a transplant site in preparation for the insertion of a hair follicle from a donor site. Some apparatus can include a plurality of hollow needles and/or a reciprocating arrangement to mechanically advance and withdraw the one or more hollow needles.
The present disclosure provides bicyclononyne based compounds and methods to prepare an antibody conjugate with a fluorophore, as well as the methods of using these conjugates for cellular imaging. In one example, the conjugate may be coupled with a quencher to absorb fluorescence from the fluorophore.
C07C 13/45 - Hydrocarbures polycycliques ou leurs dérivés hydrocarbonés acycliques à cycles condensés à système bicyclique contenant neuf atomes de carbone
C07C 211/19 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné saturé contenant des cycles autres que des cycles aromatiques à six chaînons contenant des systèmes cycliques condensés
C07C 229/28 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant saturé et contenant des cycles
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
51.
COMPOSITIONS AND METHODS FOR CONTROL OF TRANSIENT SITE-SPECIFIC COPY GAINS, GENOMIC INSERTIONS, AND REARRANGEMENTS ASSOCIATED WITH MIXED LINEAGE LEUKEMIA
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
A61K 31/7115 - Acides nucléiques ou oligonucléotides ayant des bases modifiées, c. à d. autres que l'adénine, la guanine, la cytosine, l'uracile ou la thymine
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
52.
SYSTEM FOR AND METHOD OF MEASURING BLOOD PRESSURE NON-INVASIVELY WITH LIGHT
Optical patient monitoring systems are disclosed. The system may comprise an optical coupling system configured to transmit to and receive light signals from one or more locations on a subject; an optical processing system configured to generate optical data using the received light signals; and a computer programmed to receive the optical data; determine, using the optical data, at least one indicator of blood pressure; estimate an estimated blood pressure using the at least one indicator of blood pressure; and generate a report indicative of the estimated blood pressure. The at least one indicator of blood pressure comprises one or more of near-infrared spectroscopy (NIRS) data; photoplethysmography (PPG) data, diffuse correlation spectroscopy (DCS) data, speckle contrast optical spectroscopy (SCOS) data, speckleplethysmography (SPG) data, first derivative PPG data, second derivative PPG data, first derivative SPG data, second derivative SPG data, inflow (Fin) data, outflow (Fout) data, heart rate data, physiological data, and combinations thereof. Methods for estimating blood pressure are also disclosed.
A61B 5/021 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang en utilisant des capteurs optiques, p.ex. des oxymètres à photométrie spectrale
A61B 5/318 - Modalités électriques se rapportant au cœur, p.ex. électrocardiographie [ECG]
A61B 5/369 - Modalités, c. à d. méthodes diagnostiques spécifiques Électroencéphalographie [EEG]
53.
PREVENTING IMMUNOTHERAPY-INDUCED EDEMA USING ANGIOTENSIN RECEPTOR BLOCKERS
A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p.ex. tétrazole
A system for identifying a plurality of biomarkers in a sample, including: a substrate including a plurality of microneedles projecting therefrom, each of the plurality of microneedles including a plurality of biomarker recognition molecules attached thereto, and the plurality of microneedles including a first microneedle and a second microneedle, the first microneedle including a first plurality of biomarker recognition molecules configured to recognize a first biomarker, and the second microneedle including a second plurality of biomarker recognition molecules configured to recognize a second biomarker different from the first biomarker.
An eyelid treatment system can include a contact lens that can include an inner concave surface and an outer convex surface opposite the inner concave surface. The contact lens can be configured to be placed on an eyeball of a subject. The eyelid treatment system can include a light source optically coupled to the contact lens. The light source can be configured to deliver light to an inner surface of an eyelid of the subject when the contact lens is placed on the eyeball. The inner concave surface can be configured to at least partially block light from being transmitted through the inner concave surface, such that the light propagates in a direction away from the eyeball of the subject. The light from the light source can be configured to reduce eyelid inflammation.
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
Antibodies, and antigen-binding fragments thereof, that specifically bind to bone morphogenetic protein-9 (BMP9) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.
C07K 16/22 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
59.
SYSTEMS, COMPOSITIONS, AND METHODS RELATING TO NEURODEGENERATIVE DISEASES
In some aspects, the present disclosure provides a method for determining a risk or state of a neurodegenerative disease of a subject. In some embodiments, the method comprises detecting a presence of a biomarker in a biological sample from the subject, wherein the biomarker comprises at least one of: E7EUF1, O94812, P02549, P02730, P05019, P05154, P05546, P13497, P16157, P16452, P17936, P24593, P27918, P35858, P41218, Q12797, Q13214, Q13822, Q8NI99, Q96IY4, Q99715, Q9BXN1, Q9H0B8, or a proteoform thereof. In some embodiments, the method comprises detecting a presence of a biomarker in a biological sample from the subject, wherein the biomarker comprises at least one of: P54803, P14625, P30043, P00742, A0A0D9SG88, Q5TFM2, P54803, P54803-3, P54803-4, P04196, or a proteoform thereof. In some embodiments, the method comprises determining the risk or state of the neurodegenerative disease of the subject based on the presence of the biomarker in the biological sample.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12N 15/115 - Aptamères, c. à d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
The present invention provides a method for obtaining genetically-anchored molecular signatures that are molecular signatures linked to genetic risk variants and that define mechanistic disease pathways in order to facilitate improved disease sub-classification, develop of novel rational therapeutics, and implement targeted prevention practices. The signatures can be obtained using polygenic risk scores and gene expression data, such as partitioned polygenic risk scores. In certain embodiments, the method further comprises identifying one or more key regulatory features of the genetically-anchored molecular signature by matching the genetically-anchored molecular signature with one or more perturbation molecular signatures from a perturbation data set using similarity scoring
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
Devices and methods for improving the infection-healing behavior of a biological wound are disclosed. The device can comprise: a matrix; a light-emitting layer comprising a plurality of light sources; a controller in electrical communication with the light sources, the controller being configured to execute a program stored in the controller to activate the light sources to irradiate the wound or a region adjacent the wound with light for a period of time when the device is placed over the wound; and an antimicrobial adjuvant present as part of the device in an amount effective to synergistically potentiate antimicrobial activity of the light with respect to microbes on or adjacent the wound. The wound may include microbes in a biofilm. In one embodiment, the antimicrobial adjuvant comprises a substituted naphthalene, such as menadione. In one embodiment, the antimicrobial adjuvant comprises near infrared radiation.
A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
A61L 2/08 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contact; Accessoires à cet effet utilisant des phénomènes physiques des radiations
A61F 3/00 - Pièces pour allonger les jambes naturelles
Described herein are methods for treating a carcinoma in a subject, the method comprising administering to the subject a therapeutically effective amount of (5z)-7-oxozeaenol (Oxo) or an analog thereof, optionally in combination with chemotherapy.
Described herein are methods and compositions for treating neurodegenerative diseases including Spinocerebellar Ataxia comprising administering a BACE1 inhibitor.
A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p.ex. chorée, dyskinésie
A61K 31/549 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. sulthiame ayant plusieurs atomes d'azote dans le même cycle, p.ex hydrochlorothiazide
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 27/00 - Médicaments pour traiter les troubles des sens
64.
SYSTEM FOR STABILIZED NONINVASIVE IMAGING OF MICROVASCULATURE IN THE ORAL MUCOSA
Disclosed is a system for imaging of microvasculature of tissue of a subject. The system can comprise: (a) a tissue stabilizer structured to contact the tissue of the subject to maintain a position of the region of microvasculature being imaged, and (b) an imaging instrument including: (i) a housing having an imaging section, (ii) an illumination device having a light-outputting end positioned in the imaging section for illuminating a region of the microvasculature with light, wherein the light-outputting end is offset relative to an optical axis of the imaging section; (iii) an objective lens positioned in the imaging section such that the objective lens receives at least a portion of light scattered by the region of the microvasculature, and (iv) an image detector positioned in the imaging section such that the image detector receives light redirected by the objective lens and detects microscopic images of the region of microvasculature.
65.
METHODS AND COMPOSITIONS FOR IMMUNE CELL CRISPR SCREENS
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
Disclosed are devices and methods for treating a skin condition (e.g., cutaneous neurofibroma tumors) of a subject. The device comprises: a chamber having an end wall, a side wall extending away from the end wall, and an opening opposite the end wall, wherein the side wall terminates in a contact surface for sealing against skin of a subject; a vacuum source in fluid communication with the interior space of the chamber, the vacuum source being structured to create negative pressure in the chamber; and a light source for irradiating a region of the skin of the subject with light, the light source being selected from the group consisting of laser light sources and wavelength-filtered light sources, the light source being positioned to direct the light at the region of the skin of the subject when the light source is activated to treat the skin condition.
A61B 18/20 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p.ex. de micro-ondes en utilisant des lasers
A61M 1/00 - Dispositifs de succion ou de pompage à usage médical; Dispositifs pour retirer, traiter ou transporter les liquides du corps; Systèmes de drainage
A61N 5/067 - Thérapie par radiations utilisant un rayonnement lumineux utilisant un rayonnement laser
67.
TREATMENT AND DETECTION OF CANCERS HAVING A NEURAL-LIKE PROGENITOR, SQUAMOID/BASALOID/MESENCHYMAL, OR CLASSICAL PHENOTYPE
The subject matter disclosed herein is generally directed to methods of detecting treatment refractory cancer and treatment thereof In example embodiments, specific biomarkers expressed specifically in pancreatic cancer subtypes are disclosed. The biomarkers can be used for therapeutic targeting of pancreatic cancers. The biomarkers can be used for noninvasive diagnostic methods.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
Methods and devices for the nasal administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) in neuroprotection, e.g., in neurodegenerative diseases and to reduce the risk of ischemic injury. The methods can be used, e.g., to reduce risk of injury to brain, spinal cord, and peripheral nerves from ischemia or low blood flow states possibly caused by surgery, trauma, and other conditions that decrease/impair blood flow and or oxygen delivery to the nervous system.
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminée; Leurs dérivés contenant au moins une liaison peptidique anormale
The present disclosure relates to direct immobilization of antibodies by physisorption onto plain and nanostructured metal-containing films. An exemplary method for preparing a sensor includes contacting an antibody with a surface of a film comprising an ionic compound and a metal selected from gold, silver, platinum, copper, and any combination thereof, and then contacting a blocking agent with the surface of the film to form the sensor.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
70.
RADIATION CLEAVED DRUG-CONJUGATE LINKERS ENABLE LOCAL PAYLOAD RELEASE SCLEROSIS
The present disclosure relates to drug-conjugate molecules that release a biologically active payload upon exposure to ionizing radiation. Localized x-ray irradiation releases the payload under normoxic and/or hypoxic conditions that are traditionally associated with radiotherapy resistance.
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61K 47/51 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification
71.
SYSTEMS AND METHODS FOR SORTING USING LASER PARTICLES OR CELLS
A system and method for flow sorting includes a sample loader that is configured to receive a sample that contains one or more laser microparticles, wherein each laser microparticle is configured to generate laser emission with one or more distinct spectral peaks when excited. The system further includes a spectrometer receiving the laser emission from the one or more laser microparticle and generating spectral data and a processor configured to receive the spectral data and generate a sorting signal. The system also includes a switch configured to receive the sorting signal and route the one or more microparticles to a particular one of multiple collection channels based on the sorting signal.
Disclosed is a method for regenerating and/or repairing lung tissue in a subject. The method comprises administering to a subject in need of lung tissue regeneration and/or repair a composition including (i) a carrier comprising a scaffold-forming material, (ii) cellular material selected from the group consisting of endothelial cells, epithelial cells, mesenchymal stem cells, and mixtures thereof, and (iii) pneumocytes. In one embodiment of the method, the administering is intravenously or intratracheally. The administering can be via airways to the lung. The scaffold-forming material can comprise (i) a first biopolymer having a first reactive group; (ii) a second biopolymer having a second reactive group, wherein the first reactive group and the second reactive group react via click chemistry to crosslink the first biopolymer and the second biopolymer to form a hydrogel; (iii) a porogen; and a (iv) porogen-degrading agent.
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
73.
NANOPARTICLE DOPED POLYETHYLENE GLYCOL BASED GELS AND MEDICAL DEVICES FOR DRUG DELIVERY
Provided herein are compositions, kits, and methods of making biodegradable compositions for localized drug delivery. The drug delivery compositions include one or more therapeutic agents that are dispersed within polymerized macromers of the drug delivery composition, loaded within biopolymeric nanoparticles within the drug delivery composition, or both. The release profiles of the one or more therapeutic agents are tunable based on the one or more therapeutic agents for a desired application.
A61L 27/44 - Matériaux composites, c. à d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire
The disclosure features compositions containing chimeric antigen receptor (CAR) immune cells that have been modified to reduce and/or eliminate expression or activity of a natural killer cell lectin A (NKG2A) polypeptide and/or a cluster of differentiation 94 (CD94) polypeptide, and methods for use thereof to treat a neoplasia.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
75.
SYSTEM FOR AND METHOD OF PLANNING AND REAL-TIME NAVIGATION FOR TRANSCRANIAL FOCUSED ULTRASOUND STIMULATION
A system for planning and real-time navigation for transcranial focused ultrasound stimulation (tFUS) including receiving an image of a head of a subject, an acoustic beam profile simulation module configured to generate a subject-specific set of acoustic beam profiles based on the subject's head; subject-specific set of acoustic beam profiles configured to account for acoustic propagation effects through the subject's skull; a planning module coupled to the acoustic beam profile simulation module configured to generate an acoustic intensity scalp map for a target region and to generate a three-dimensional (3D) visualization of a selected beam profile from the subject-specific set of acoustic beam profiles; and a real-time navigation module coupled to the acoustic beam profile simulation module configured to generate a real-time 3D visualization of an acoustic beam for tFUS for a current position of a transducer around the head of the subject based on current position data and the subject-specific set of acoustic beam profiles.
Systems and methods are provided that include acquiring, at a plurality of different times, an induced voltage within a plurality of coils arranged about the subject's head and positioned within a variable magnetic field. The method also includes acquiring electroencephalogram (EEG) data from a plurality of EEG sensors, wherein each EEG sensor is paired with a respective one of the plurality of coils. The method also includes determining, for each of the plurality of times, a position of each coil in the plurality of coils positioned in the variable magnetic field utilizing the induced voltage at the particular time and using the position of each coil in the plurality of coils to correlate the EEG data with at least one of an anatomical image or a functional image of the head of the subject.
A61B 5/291 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG]
A61B 5/369 - Modalités, c. à d. méthodes diagnostiques spécifiques Électroencéphalographie [EEG]
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre
Systems and methods are provided that permanently modify an airway, such as a nasal airway without surgical intervention. The system to modify an airway can include one or more nasal inserts having different geometries or capable of being configured into different geometries to incrementally adjust bone or cartilage in the nasal airway over an extended period of time.
Provided herein are methods for treating a brachyury-associated cancer or neoplasm, e.g., chordoma, with a type I interferon in a subject in need thereof. The methods further include treating the brachyury-associated cancer or neoplasm with interferon alpha or interferon beta by injection of interferon protein into a subject in need thereof, wherein the interferon can be an interferon polypeptide or an interferon nucleic acid formulated for expression.
C12N 15/79 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
Provided herein are methods for diagnosing ALS, or determining risk of developing ALS. The methods include detection of a fusion as described herein. The methods can include detecting genomic fusions, fused transcripts, or fusion proteins (where proteins are produced) as described herein.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
80.
GENETICALLY ENCODED SYSTEMS FOR GENERATING OXYGEN IN LIVING EUKARYOTIC CELLS
C12N 1/38 - Stimulation chimique de la croissance ou de l'activité par addition de composés chimiques qui ne sont pas des facteurs essentiels de croissance; Stimulation de la croissance par élimination d'un composé chimique
The present document relates to microfluidic devices and microfluidic systems for capturing a target of interest. Also described herein are methods of isolating or capturing such targets.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
B01D 15/38 - Adsorption sélective, p.ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p.ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
B01D 15/10 - Adsorption sélective, p.ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement
Methods of detecting and measuring positron emission for tumor margin assessment are described. The preferential uptake of radiotracers by certain tumor types provides a measurable parameter for distinguishing between healthy and cancerous tissue to enhance tumor margin determination. The methods provide more accurate margin delineation and reduced tissue resection size relative to conventional breast conserving surgery techniques.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
000 magnet and one or more gradient coils, and an imaging radiofrequency coil. A method for manufacturing is provided in which the arrangement of magnetic elements is optimized to produce a target magnetic field within a target scanning volume.
G01R 33/383 - Systèmes pour produire, homogénéiser ou stabiliser le champ magnétique directeur ou le champ magnétique à gradient utilisant des aimants permanents
G01R 33/20 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique
G01R 33/3875 - Compensation des inhomogénéités utilisant des ensembles de bobines de correction, p.ex. compensation active
Described herein are systems and methods for improving the performance of and compliance with wearable garments. In some embodiments, a system comprises one or more sensors integrated within a wearable garment. The sensors are configured to generate data responsive to pressure exerted by the wearable garment on a user; and one or more processors coupled to the one or more sensors. The processors are configured to process the generated data to determine a duration of use of the wearable garment by the user; and in response to determining that the duration of use is less than a predetermined duration of use threshold, generating one or more notifications.
A61F 13/08 - Bandages ou pansements; Garnitures absorbantes spécialement conçus pour les pieds ou les jambes; Coussinets pour cors; Anneaux pour cors pour comprimer les anévrismes
An imaging and biopsy device, including: a tethered capsule that is configured to be swallowed; a first optical fiber transmitting an electromagnetic radiation that at least partially impacts an anatomical structure; and a biopsy apparatus configured to collect tissue from the anatomical structure, the electromagnetic radiation at least partially or temporarily impacting the biopsy apparatus, and at least a portion of the first optical fiber and the biopsy apparatus being associated with the tethered capsule.
A61B 1/05 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision caractérisés par le fait que le capteur d'images, p.ex. l'appareil photographique, est placé dans la partie de l'extrémité distale
An image may be reconstructed from sensor data, which may include optical imaging data such as diffusion optical tomography ("DOT") data. The sensor data are received by a computer system. A machine learning model is accessed with the computer system, where the machine learning model includes a first subnetwork that receives sensor data as an input and generates an intermediate image as a first output, and a second subnetwork that receives the first output from the first subnetwork and generates an enhanced image as a second output. The sensor data are input to the machine learning model using the computer system, generating an enhanced image as an output. The enhanced image may have higher spatial resolution, reduced noise, or other improved image quality. Structural images may be passed as an additional input to the second subnetwork of the machine learning model to increase the spatial resolution of the enhanced image.
G06T 19/20 - Transformation de modèles ou d'images tridimensionnels [3D] pour infographie Édition d'images tridimensionnelles [3D], p.ex. modification de formes ou de couleurs, alignement d'objets ou positionnements de parties
Systems and methods are provided for a hybrid superconducting-permanent magnet MR1 system. Permanent magnet elements may be used to supplement or shape the magnetic field produced by the superconducting windings. The hybrid design may increase field homogeneity or reduce the required bore length, thereby reducing the total system cost.
G01R 33/3815 - Systèmes pour produire, homogénéiser ou stabiliser le champ magnétique directeur ou le champ magnétique à gradient utilisant des électro-aimants avec des bobines supraconductrices, p.ex. leurs alimentations
G01R 33/383 - Systèmes pour produire, homogénéiser ou stabiliser le champ magnétique directeur ou le champ magnétique à gradient utilisant des aimants permanents
G01R 33/385 - Systèmes pour produire, homogénéiser ou stabiliser le champ magnétique directeur ou le champ magnétique à gradient utilisant des bobines de champ magnétique à gradient
89.
COMPOSITIONS AND METHODS FOR REDUCING CELL THERAPY IMMUNOGENICITY
This application provides, in part, methods and compositions for decreasing the immunogenicity of cell therapies (e.g., CAR-T cell therapies) using inhibitors of transporter associated with antigen processing (TAPi) and oligonucleotides that decrease the expression of an immunogenic proteins (e.g., MHC Class I and Class II).
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
e.g.e.g.e.g., a DOTA-chelated 68e.g.transtrans-cyclooctene moiety in its structure). As described herein, the imaging and theranostic methods of this disclosure advantageously allow for rapid corporeal elimination of radionuclides once imaging or theranostic treatment is completed.
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
The disclosure is directed to methods and compositions for treating cancers characterized by cells comprising chimeric antigen receptors (CARs) that bind CD70 and T-cell engaging antibody molecules (TEAMs) that bind CD33, nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind CD70 and/or TEAMs that bind CD33, and compositions and methods related thereto.
Described herein are compositions comprising zinc fingers and methods of use thereof for the treatment of nucleotide repeat expansion disorders such as Ewing Sarcoma.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p.ex. kétorolac, physostigmine
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
The disclosure relates to methods and kits for detecting tau, e.g., tau that is phosphorylated at amino acid position T181 (pTau181), tau that is phosphorylated at amino acid position T217 (pTau217), and/or total tau. The disclosure further provides methods for distinguishing between individuals whose cognitive condition will remain stable and whose cognitive condition will decline during their lifetime. The disclosure also provides methods for determining the eligibility of individuals for participation in clinical trials for Alzheimer's disease treatments. Also provided are methods for distinguishing between individuals with Alzheimer's disease and non-Alzheimer's dementia, and for monitoring response to treatment for Alzheimer's disease.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
95.
AMPLIFICATION ASSAYS USING CRISPR-CAS BASED DETECTION
Described in various embodiments herein are tiled amplification nucleic acid detection systems and uses thereof. In some embodiments, the nucleic acids amplified and detected are cell free DNA (cfDNA).
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
The present invention relates to treating neurodegeneration (e.g., a neurodegenerative disorder), enhancing cognitive function, delaying or reducing cognitive decline, enhancing the metabolism, and/or improving memory in patients in need thereof, e.g., patients diagnosed with a neurodegenerative disorder or displaying one or more symptoms of a neurodegenerative disorder (e.g., declining cognitive function) by administering Pla2g2f to a subject or increasing expression of Pla2g2f in a cell of a subject.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
98.
SYSTEMS AND METHODS FOR NONCONTACT ULTRASOUND IMAGING
Systems and methods for non-contact, non-invasive image construction of interior tissue are provided. Electromagnetic (EM) waves maybe used to transmit through a high acoustic material or barrier, such as a bone, where the EM wave is then absorbed and converted to ultrasound (US) or audible band acoustic longitudinal waves or shear waves once past the high acoustic impedance barrier. The EM to acoustic converted waves are generated through thermoelastic mechanisms. This enables acoustic waves to propagate in the soft tissue on the opposing side of the barrier while minimizing reverberation and clutter. The US waves propagate within the tissue and may be measured using a detector, such as coherent lidar or optical band multipixel camera noninvasively outside the tissue. Furthermore, a phased array can be used to steer and shape the acoustic radiation pattern of the acoustic waves in the soft tissue beyond the bone or high acoustic impedance barrier.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio
A61B 5/0507 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio utilisant des micro-ondes ou des ondes térahertz
99.
SCAFFOLDS FOR MODIFYING IMMUNE CELLS AND THE USES THEREOF
The present invention discloses compositions and methods for modulating the immune system in a subject. The compositions of the present invention comprise a porous scaffold biomaterial comprising active agent. The method of the present invention comprises administering to a subject a scaffold composition comprising active agent, thereby modulating the immune system in a subject.
A61K 47/36 - Polysaccharides; Leurs dérivés, p.ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
The present disclosure provides photocleavable rhodamine probes that facilitate live- and fixed-cell immunofluorescence. The ultra-fast spirocyclization of the dye following cleavage depletes the fluorescence signal, enabling cyclic multiplexed imaging.
C07D 491/107 - Systèmes condensés en spiro avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène
C07D 491/22 - Composés hétérocycliques contenant dans le système cyclique condensé, à la fois un ou plusieurs cycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, et un ou plusieurs cycles comportant des atomes d'azote comme uniques hétéro- dans lesquels le système condensé contient au moins quatre hétérocycles
C09B 11/24 - Phtaléines contenant des groupes amine
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire